Modular Solution for Cosmetics Compliance
Check the Conformity of your Formulas
Secure your regulatory documents for each zone
Optimize on-site risk management
Manage your Safety Data Sheets efficiently
Automate your regulatory monitoring
Ensure the traceability of your substances
Maintain good HSE risk management
Learn the key differences between US and EU cosmetic regulations and how to export your products from the USA to Europe in full compliance.
Recevez une fois par mois les dernières actus réglementaires et conseils d’experts.
Upstream authorisation dossiers for hexavalent chromium compounds lack specificity and transparency, leading to incomplete risk assessments. Stakeholder involvement is crucial for future applications to ensure effective risk management. Prepare for the end of coverage in 2024 by starting the application process early. Join the REACH Authorisation Alliance for strategic guidance and decision-making support.
The European Commission has authorized six uses of three substances: sodium dichromate, chromium trioxide, and sodium chromate, with review periods expiring on September 21, 2024. These authorizations involve companies like ZF Luftfahrttechnik GmbH and Wesco Aircraft EMEA Limited.
The European Commission's new regulation extends the validity of pre-registrations for REACH phase-in substances until December 31, 2019. Starting in 2020, pre-registrations will expire, requiring companies to undergo an inquiry for registration, with updated tonnage band calculations.
ECHA has recommended adding 18 substances of very high concern to the REACH Authorisation List (Annex XIV) to prevent their use as substitutes for other regulated substances. The final decision will be made by the European Commission and other EU bodies.
According to a report by the European Commission, the REACH, CLP and BPR regulations represent almost 1/3 of the regulatory costs that weigh on the chemical industry!
With Brexit looming, only 48% of British companies have transferred their chemical registrations to EU-27 entities, risking the availability of over 700 substances in the EU market. The uncertain political landscape adds to the urgency for companies to prepare for a no-deal scenario.
